On February 27, the FDA published proposed regulations to update nutrition fact labels that would make the familiar labels undergo a dramatic change for the first time...

All about diabetic macular edema (DME) and three tips for avoiding it.

On May 29, the American Diabetes Association (ADA) and the American Nurses Association (ANA) appeared before the California Supreme Court to argue whether designated...

iHealth Labs recently announced the launch of its wireless Smart-Gluco Monitoring system in the US. Similar in principle to LifeScan's OneTouch VerioSync ( cleared by...

On February 22, Slow Food San Francisco hosted the annual Childhood Obesity Bay Area Conference, which featured Dr. Robert Lustig of the University of California, San...

A game-changing therapy for type 2 diabetes? Plus, the latest on predictive low glucose suspend, faster insulin, and a better Bydureon.

On July 25, Bristol-Myers Squibb (BMS) and AstraZeneca (AZ) announced the resubmission of Forxiga (dapagliflozin), their SGLT-2 inhibitor for type 2 diabetes, to the FDA...

The technology giant, Google recently announced that it is working to develop a contact lens that could non-invasively monitor glucose levels from tears. The smart...

How do you stay healthy and happy with diabetes? Kerri shares five lessons she has learned over the years.

On January 7, the FDA announced updated standards for the accuracy of blood glucose monitors for use in both the home and healthcare facility settings. These standards...

What apps are best for diabetes? What we learned at this year’s AADE 2013.

The first quarter of 2013 has been eventful for Johnson & Johnson Diabetes Care. Animas Corporation submitted the Animas Vibe insulin pump to the FDA, integrated...

Last month, in early September, results from the DPP-4 inhibitor cardiovascular outcomes trials SAVOR-TIMI 53 (for Bristol Myers Squibb and AstraZeneca’s Onglyza) and...

On March 4, Medtronic announced the creation of a new pilot program with Aetna to provide an insulin pump to up to 300 fully insured members with uncontrolled type 2...

Five things people with diabetes need to know about the Affordable Care Act.

Samepage Health launched VisitPrep , a tool that helps patients organize their medical questions before going to their healthcare provider (HCP). The tool asks for the...

Xeris announced last month the beginning of its phase 2 trial of a room temperature stabilized glucagon. The trial will compare Xeris’ glucagon to Eli Lilly’s glucagon...

On April 3, an FDA Advisory Committee voted an overwhelming 13-1 in favor of approving MannKind’s ultra-rapid-acting inhaled insulin Afrezza for type 1 diabetes. The...

MannKind’s inhalable ultra-rapid-acting insulin Afrezza has its day at the FDA – find out what it can do for patients and how to speak up!

Last month, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) released its safety review of incretin-based therapies for diabetes. It...